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Abstract
Multidrug- and extensively drug-resistant tuberculosis have emerged as grave threats to public health worldwide. Very few
active drugs are available or likely to become available soon. To address these problems we revisited a classical observation,
the applicability of phenothiazines as antimicrobial drugs. Within this pharmacological class we selected thioridazine, which
is most efficacious and least toxic, when used as an antipsychotic drug. We tested thioridazine monotherapy in the Balb/c
mouse model for its activity to treat both susceptible and multidrug-resistant tuberculosis by a two months daily oral
administration of 32 and 70 mg/kg. In addition, we tested its additive value when combined with a standard first-line
regimen for susceptible tuberculosis. Thioridazine treatment resulted in a significant reduction of colony-forming-units of
the susceptible (24.4 log CFU, p,0.05) and multidrug-resistant tuberculosis bacilli (22.4 log CFU, p,0.009) in the lung
both at one and two months after infection, compared to controls. Moreover, when thioridazine was added to a regimen
containing rifampicin, isoniazid and pyrazinamide for susceptible tuberculosis, a significant synergistic effect was achieved
(26.2 vs 25.9 log CFU, p,0.01). Thioridazine may represent an effective compound for treatment of susceptible and
multidrug-resistant tuberculosis. The phenothiazines and their targets represent interesting novel opportunities in the
search for antituberculosis drugs.
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Introduction
The phenothiazines are a class of antipsychotic drugs that have
activity against the plasma membrane of the responsive eukaryotic
cells and, hence, also against similar membranes of prokaryotic
cells. The broad spectrum antimicrobial activity of chlorproma-
zine, the first commercially available phenothiazine, was first
recognized in the 1950s; its activity was thought to result from
binding to penicillin binding proteins, thereby inhibiting cell wall
synthesis [1]. The serious side effects, including hepatotoxicity and
agranulocytosis, associated with chronic use of chlorpromazine for
psychoses limited the interest in its antimicrobial activity.
In the following decades less toxic phenothiazine derivates,
including thioridazine, were developed. They also proved to have
a potent in vitro activity against a variety of bacteria. However,
many effective antibiotics became available during the so-called
golden era of antibiotics and phenothiazines were thus no longer
considered in the treatment of bacterial infections [2].
The activity of the phenothiazines against mycobacteria has
gained renewed attention due to the ongoing spread of multidrug-
resistant tuberculosis (MDR-TB), i.e. tuberculosis caused by
Mycobacterium tuberculosis complex bacteria that are resistant to at
least isoniazid and rifampicin [2]. These two drugs are the most
potent drugs used in TB treatment. Worldwide, on average 5.3%
of the TB cases can be classified as MDR-TB, according to the
WHO report of March 2008 [3]. The emergence of MDR-TB
strains that reveal additional resistance against fluoroquinolones
and aminoglycosides (extensively drug-resistant TB, or XDR-TB)
marks a new point in the history of the long-lasting battle against
TB [3].
New drugs are in the pipeline, including the diarylquinoline
TMC207 which was recently evaluated in a phase II study [4,5].
Still, it will take years before their efficacy and safety have been
evaluated and before they become available in resource-poor
settings where the burden of resistance is largest and untreatable
TB cases emerge rapidly [4,5].
The in vitro antituberculosis activity of thioridazine has been well
established [6,7]. In addition, exposure of immune cells to
thioridazine has been shown to promote the release of cytokines
involved in the mounting of a response to mycobacteria [6]. These
cytokines are also markers of progression of a tuberculosis
infection to active disease status [8]. Thioridazine has the
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period of time and has become relatively inexpensive. Moreover,
thioridazine has been used extensively as an antipsychotic drug,
generally without causing severe side effects [2].
Given the emergence of resistant forms of tuberculosis and the
favourable antimicrobial and immunomodulatory characteristics
of thioridazine, we revisited a classical observation, the applica-
bility of phenothiazines in the treatment of bacterial infections.
Methods
Ethics Statement
All animal work was performed in conformity with the local
Ethical Committee for Experimentation in Animals in Mexico;
these are laid out in document NOM 062-ZOO-1999: Technical
rules for the production, care and use of laboratory animals. The
study was approved by the institutional review board at the
National Institute of Medical Sciences and Nutrition Salvador
Zubira `n under file number PAT-037-06-09-1.
Experimental model of tuberculosis infection in mice
The tuberculosis Balb/c mouse model has been described in
detail previously [9]. In short: Male Balb/c mice were obtained
from Jackson Laboratories (Bar Harbor, Maine, USA) and used at
6–8weeksofage.VirulentM.tuberculosisH37RvandaMDRclinical
isolate (code 900) isolated from a tuberculosis patient in Monterrey
city, northern Mexico, were cultured in Youman’s modification of
the Proskauer/Beck medium. The MDR strain, which belongs to
the X1 genotype based on spoligotyping, was resistant to rifampicin
(MIC 100 mg/ml), isoniazid (MIC 3.13 mg/ml), ethambutol (MIC
8 mg/ml) and streptomycin (MIC.100 mg/ml); its rifampicin
resistance resulted from a Ser531Leu mutation in the rpoB gene.
Colonies were harvested after four weeks and suspended in
phosphate-buffered saline (PBS) containing 0.05% Tween 80 and
shaken for 10 min together with glass beads. The suspension was
centrifuged for 1 min at 3506g to sediment large clumps of
bacilli. Thereafter, a preliminary microscopic bacterial count was
conducted by analyzing the supernatant at a known ratio of
volume to area, and counting 10 random fields after staining by
the Ziehl-Neelsen staining technique. The suspension was
adjusted to 2.5610
5 bacteria in 100 ml of PBS and stored at
270uC. Before using the bacteria taken from the freezer stock,
they were recounted, and the viability was checked as previously
described [10].
To achieve intratracheal infection, mice were anaesthetized by
intraperitoneal application of 56 mg/kg thiopental. Thereafter,
the trachea was exposed via a small midline incision, by injection
of 2.5610
5 viable bacteria in 100 ml of PBS. The incision was
sutured with sterile silk, and the mice were maintained vertically
until the effects of the anaesthetic had worn off. Infected animals
were housed in groups of five in cages fitted within micro-isolators.
Drug dosing and administration
First, a dose finding study was undertaken in mice infected with
H37Rv. The selection of the appropriate thioridazine dose was
done following previous publications [11]; we tested 16, 32 and
70 mg/kg dosages. Treatment was started 60 days after infection,
when tuberculosis was already well advanced. Surviving animals
were randomly allocated to the three treatment groups of 20 mice
each. The thioridazine dosages were administered daily as
dissolved drug in distilled water in a total volume of 0.1 ml
administered daily by an intragastric cannula; treatment duration
was 2 months.
In a second experiment, we repeated infection and treatment
using the clinical MDR-TB isolate. Based on findings in
experiment one, only 32 mg/kg and 70 mg/kg of thioridazine
were used.
In the third experiment 60 mice were infected with H37Rv.
Mice surviving 60 days after infection were randomly assigned to
three experimental groups. The first group of 20 infected mice was
treated by conventional chemotherapy: rifampicin (10 mg/kg),
isoniazid (10 mg/kg), and pyrazinamide (30 mg/kg), administered
daily by an intragastric cannula, plus 32 mg/kg of thioridazine
administered daily by the same route in separate solutions. The
second group of 20 infected mice exclusively received the
conventional chemotherapy, and the control group was solely
treated with the diluent. Again, treatment duration was 2 months.
All three experiments were done in duplicate. In all experi-
ments, four mice per group were sacrificed by exsanguination
under terminal anaesthesia after 2, 4 and 8 weeks of treatment; no
animals were sacrificed at the start of treatment. The bacillary load
of the lungs was determined by colony forming units (CFU)
quantification and observation of the histological damage as
described below.
In all experiments, a subset of animals from each group was
sacrificed at one and two month intervals. All data points are
means (6SD) of results in four animals and represent results in two
separate experiments that yielded highly reproducible results.
Bacteriological and histological assessment of infected
lungs
During dissection of the animals, one lung lobe (right or left) was
immediately frozen by immersion in liquid nitrogen and used for
colony counting, while the other was perfused with 10%
formaldehyde and used for histopathology analysis. For CFU
determination, frozen lungs were disrupted in a Polytron
homogeniser (Kinematica, Luzern, Switzerland) in sterile 50 mL
tubes containing 3 ml of isotonic saline. Four dilutions of each
homogenate were spread onto duplicate Middlebrook 7H10 agar
plates enriched with OADC; plates were incubated for 21 days.
Four animals were sacrificed at each time point and all
experiments were performed in duplicate; hence, the data points
are the means of eight animals.
For the histological study, after two days of fixation, parasaggital
sections were taken through the hilus from 4 lung lobes per time
point in two separate experiments, and these were dehydrated and
embedded in paraffin, sectioned at 5 mM and stained with
haematoxylin and eosin. The percentage of lung affected by
pneumonia was measured using a Zidas Zeiss image analysis
system. Measurements were done in a blinded manner, by a
certified pathologist, and data are expressed as the mean of 8
animals 6SD.
Statistics
A one way analysis of variance (ANOVA) and Student’s t-test
were used to compare numbers of CFUs and morphometry
determinations in infected mice treated with thioridazine and non-
treated control animals. A difference of p,0.05 was considered
statistically significant.
Results
In the first experiment, in animals infected with the drug-
susceptible M. tuberculosis reference strain H37Rv, the lowest dose
of thioridazine (16 mg/kg) was almost ineffective as this did not
result in a clear reduction of the number of bacilli in the lung (data
not shown), while the intermediate (32 mg/kg) and high dose
Thioridazine for MDR-TB
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As shown in Figure 1, after 30 days of treatment a significant four
fold decrease in the lung bacillary loads was found in the
thioridazine-treated mice (6610
5,S D1 610
5), compared to the
control group (2.7610
6 SD 1.5610
6,p ,0.019). Thereafter, a
slight rise in the number of CFU was observed in both treated
groups by day 60. However, a five fold decrease was seen in the
treated animals (1.1610
6,S D5 610
4) when compared to the
control group (5.5610
6,S D6 610
5,p ,0.05). Latter group showed
a progressive increase in CFUs in the lung (Figure 1). These results
on bacillary loads correlate well with the morphometric observa-
tions, which showed a significant decrease of the lung area affected
by pneumonia in the treated animals when compared to the non-
treated control group (Figure 1B).
In the second experiment we observed that the dose of
70 mg/kg of thioridazine, daily administered in mice infected
with an MDR-TB strain significantly reduced the CFUs at 30 and
60 days (5.1610
5,S D6 610
4) after initiation of treatment
(p,0.009), whereas CFUs rose progressively in the untreated
control animals (2.75610
6,S D5 610
4. Figure 2). A lesser, but still
significant decrease of the pulmonary bacillary load was observed
in MDR-TB infected animals treated with 32 mg/kg of thiorid-
azine (p,0.025). In agreement with this observation, both doses
resulted in a lower percentage of the lung being involved in
pneumonia from day 30 onwards (Figure 2B).
In the third experiment, mice infected with H37Rv were treated
with conventional chemotherapy alone, or in combination with
the 32 mg/kg dose schedule of thioridazine. We chose this dose
considering a lower degree of toxicity and a nearly equal efficacy
in the reduction of CFUs compared to the highest dose (70 mg/kg)
in the second experiment. Both groups receiving only standard
anti-tuberculosis therapy showed an important decrease in CFUs
at every time point. However, the combination of standard anti-
tuberculosis therapy and thioridazine significantly accelerated the
reduction of CFUs at every time point of the experiment (Figure 3).
In fact, this treatment achieved the fastest rate of clearance of
Figure 1. Effect of Thioridazine administration on the bacillary loads (CFU) and histological damage of mice infected with drug
susceptible strain H37Rv strain. (A) Both doses of 32 (T32) and 70 (T70) mg/kg of thioridazine administered daily from day 60 after infection
significantly reduced CFU by day 30 (black bars) and 60 (white bars) after initiation of treatment. CFU rose progressively in the untreated control
animals. (B) In the thioridazine treated animals, the percentage of the lung surface affected by pneumonia was significantly smaller in thioridazine
treated- than in control animals after one (black bars) and two months (white bars) of treatment. Data is expressed as means 6 SD, 8 mice per time
point, asterisks represent statistical significance (p,0.05).
doi:10.1371/journal.pone.0012640.g001
Figure 2. Effect of Thioridazine administration on the bacillary loads (CFU) and histological lung damage of mice infected with the
MDR-TB strain. (A) In comparison with the none-treated control group of mice, both doses of thioridazine significantly reduced the CFU, 30 (black
bars) and 60 (white bars) days after initiation of treatment. CFU rose progressively in the untreated control animals. (B) In the thioridazine treated
animals, the percentage of the lung surface affected by pneumonia was found significantly lower than in control animals after one (black bars) and
two months (white bars) of treatment. Data is expressed as means 6 SD, 8 mice per time point, asterisks represent statistical significance (p,0.05).
doi:10.1371/journal.pone.0012640.g002
Thioridazine for MDR-TB
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12640bacilli at day 15 (9610
5,S D1 610
5 vs 1.46610
6,S D2 610
5,
p,0.04), with CFU values being significantly lower than those
achieved by application of the sole standard anti-tuberculosis
treatment at days 30 (6610
5,S D1 610
4 vs 1.24610
6,S D1 610
5,
p,0.006) and 60 (5610
5,S D3 610
4 vs 8610
5,S D6 610
4,
p,0.01).
Thioridazine treatment significantly decreased the extent of
lung consolidation. Figure 4 depicts the lung histology after 120
days of infection by M. tuberculosis H37Rv (4A–4B) and the MDR-
M. tuberculosis stain (4C–4D) in untreated mice (Figure 4A and 4C)
and in the mice that received thioridazine treatment (Figure 4B
and 4D).
Discussion
Thioridazine treatment results in significant reductions in the
number of bacilli in the lung as well as in the percentage of the
lungs affected both in susceptible and multidrug-resistant TB in
the Balb/c mouse model. The effect of thioridazine was achieved
both when the drug was used solely and when applied within a first
line antituberculosis regimen. The Balb/c tuberculosis model has
been used extensively to test different forms of therapy [12–14],
confirming that it is highly suitable to explore the efficiency of new
drugs or immunotherapy; this is the first study to explore efficacy
of a novel drug in MDR-TB infection. The model is based on the
airway route of infection which is the most common pathway of
infection in humans; intratracheal infection ensures equal
distribution over both lungs and accurate control of the infecting
dose. The highest rate of bacterial multiplication in the lung
correlates with the extent of tissue damage (pneumonia), in
coexistence with a bias to Th2 pattern, decline of Th1 response
and death of infected animals [9,14]. We started treatment two
months post-infection, a timepoint at which infected animals suffer
from progressive tuberculosis with high number of viable bacilli
and lung consolidation and mount an increasingly Th2-driven
response, to mimic the situation at initial presentation of patients
in high-burden, low-income settings. This is different from a
previous study by Martins et al. [15] which used a 16 mg/kg dose
of thioridazine and started treatment 30 days after intraperitoneal
infection of Balb/c mice with 10
6 CFU; in that study, bacterial
loads in the lungs of the mice reduced by 7 logs after 310 days of
treatment, but no complete sterilization was achieved. Incomplete
sterilisation in that study may have resulted from the use of
peritoneal delivery, causing the colonisation of liver and spleen
tissues and providing subsequent opportunities for re-infection of
the lung. High concentrations of thioridazine are needed for
complete inhibition of replication in an aqueous milieu; presum-
ably, mycobacteria in transit via the lymphatic or vascular
channels will not be significantly affected by the presence of the
compound.
Owing to the high infecting dose with airway delivery, the use of
thioridazine monotherapy and, in experiment three, low doses of
isoniazid (10 mg/kg) and pyrazinamide (30 mg/kg), the reduction
in bacillary load was slower than in previous studies [15,16]; in a
recent study, 6 months of first line treatment with higher isoniazid
(25 mg/kg) and pyrazinamide (150 mg/kg) doses were needed to
achieve sterilisation, after infection with 1.0610
5 viable bacteria
[16], as opposed to the 2.5610
5 viable bacteria used in the current
study.
Thioridazine is now out of patent and its resulting low cost is
advantageous in areas where the cost of second-line drugs for
MDR-TB bars their use. In areas where second line drugs are
available, adding thioridazine to an optimized background
regimen may improve therapy outcome, which, to date, has been
disappointing [17,18]. In fact, small-scale studies of the ‘‘compas-
sionate use’’ of thioridazine in XDR-TB patients who failed to
respond to any antibiotic regimen have already shown encourag-
ing results [17]. The additional efficacy of thioridazine within an
optimized background regimen should be subject of future mouse
model studies and thereafter randomized controlled trials.
Importantly, thioridazine is lethal to dormant M. tuberculosis in
both non-replicating persistent stage 1 and 2 cultures. In the non-
replicating persistent stage 1, this is the result of the activity of
thioridazine against bacterial respiration. In stage 2, the actual
pathway of action remains unknown [19]. As most common anti-
tuberculosis drugs are active against actively replicating bacilli
only, these dormant bacilli, or persisters, are considered the main
reasons for late relapses. Its activity against persisters implies that
addition of thioridazine to primary treatment regimens in pan-
susceptible TB may prevent relapses and allow shortening of
treatment. The synergistic effect of thioridazine when combined
with first-line TB treatment (Figure 3), which was previously
observed in vitro [20], may be an added advantage in the quest to
shorten treatment of pan-susceptible TB. On the other hand, the
activity of thioridazine, measured by bacillary load reduction,
seems at its maximum in the first month of treatment, to plateau in
the second month (Figures 1, 2 and 3). This phenomenon has also
been noted in a previous mouse model study, where after 4 months
of treatment, activity increased again [15]. This difference in
bactericidal activity over time seems to suggest that different
cellular functions are targeted at different times or that the
availability of a single important target differs over time.
Proteomics studies involving the currently known target of
thioridazine should address this issue, which may be of critical
importance for the inclusion of thioridazine in TB treatment
regimens.
Acquisition of thioridazine resistance is a less likely explanation
of the decrease in bactericidal activity over time. Thioridazine has
multiple mechanisms of action, including interference with cell
Figure 3. Effect of combined treatment with standard anti-
tuberculosis treatment and thioridazine on lung bacillary load
in mice infected with M. tuberculosis H37Rv. Animals were treated
from day 60 with conventional chemotherapy alone (isoniazid [H],
rifampicin [R] and pyrazinamide [Z], gray bars), or in combination with
thioridazine 32 mg daily (black bars). In comparison with untreated
control mice (white bars), both treatments produced significant
reduction of bacilli loads after 30 and 60 days of treatment, being
higher and faster in the combined treatment group. Data are expressed
as means 6 SD, 8 mice per time point, asterisks represent statistical
significance (p,0.05). T32 HRZ, first line anti-tuberculosis treatment
with adjunctive thioridazine 32 mg/kg; HRZ, first line treatment only; C,
controls.
doi:10.1371/journal.pone.0012640.g003
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inhibition of adherence of calcium, which may be lethal for cells
[2,19,21]. Therefore, the occurrence of mutations in the genome
of M. tuberculosis inducing resistance in bacterial (sub)populations is
not likely. Recently, the sigma factor network has been described
as a protective mechanism for thioridazine-induced cell wall
damage of M. tuberculosis [21]. Prolonged exposure to thioridazine
can lead to partial inactivation of macrophages [22]; whether this
affects the immune response against mycobacteria or counteracts
the T-cell mediated immunomodulatory effects of thioridazine [8]
and partially explains the plateau in CFU counts should be subject
of future experiments.
The in vitro minimum inhibitory concentrations (MIC) for pan-
susceptible, multidrug- and extensively drug-resistant M. tuberculosis
isolates are uniform at 4 mg/ml [7]. In humans, thioridazine
plasma concentrations up to 4 mg/ml are unachievable; 0.5 mg/ml
is the acceptable maximum [23]. Fortunately, M. tuberculosis
bacteria residing in macrophages are susceptible to thioridazine
even at 0.1 mg/ml, since macrophages concentrate thioridazine in
the vacuoles where M. tuberculosis resides [2,6]. Lung tissue can
efficiently concentrate the phenothiazines [24] and this may
explain that the anti-tuberculosis activity in vivo is higher than
expected on basis of in vitro MICs. In our murine model, the
concentrations of 32 and 70 mg/kg resulted in significant
reductions of the number of bacilli and the pathology in the lung.
Future studies should investigate the pharmacokinetics of thiorid-
azine in mice and compare these with human data to establish
whether the doses chosen in our present study are comparable to
maximum dose sizes used in patients.
Interestingly, the MDR M. tuberculosis strain used in this study
proved less virulent than M. tuberculosis H37Rv, based on the lower
CFU counts over time in the control groups (Figure 1 and 2).
Based on the activity of thioridazine against M. tuberculosis H37Rv
(Figure 1) and the fact that its efficacy is unrelated to strain type or
levels of first- or second-line drug resistance [7,23], it is likely that
its activity would have been equal if a strain of higher virulence
had been used. Still, this should be addressed in future studies.
Cardiotoxicity is a concern for all phenothiazines, including
thioridazine: in patients managed with thioridazine there are
almost twice as many sudden deaths due to cardiac failure as in the
general population. Rarely, thioridazine may induce episodes of
torsade-de-pointes resulting in sudden death; there are 10 to 15
such events in 10,000 person-years of observation [25]. This issue
is complicated by the fact that other drugs involved in treatment of
MDR-TB, notably moxifloxacin and to a lesser extent linezolid,
have been shown to induce QT-interval prolongation and episodes
of torsade-de-pointes [26,27]. Their combined use with thiorid-
azine may further increase the cardiotoxicity.
In summary, thioridazine shows significant activity against
drug-susceptible as well as multidrug-resistant M. tuberculosis in a
Figure 4. Representative lung histopathology from control- and treated mice after 60 days of thioridazine administration (120 days
after infection). (A) Extensive lung consolidation (arrows) is visible in control animals after 120 days of infection by drug-sensible control strain
H37Rv. (B) In contrast, less pneumonia (arrow) is seen in the lung of mice treated with thioridazine 32 mg/kg daily by intragastric cannula. (C) Control
mice after 120 days of infection with MDR strain show extensive pneumonic areas (arrow). (D) In comparison, less lung consolidation (arrow) is seen in
the lung of mice infected by the MDR-TB strain and treated daily during two months with 70 mg/kg of thioridazine (micrographs 2006magnification;
hematoxylin/eosin stain).
doi:10.1371/journal.pone.0012640.g004
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represent interesting novel opportunities in the search for active
compounds for treatment of MDR-, or XDR-TB. Its activity
against multi- and extensively drug-resistant isolates, low price,
good availability, encouraging results in compassionate use and
lack of cross-resistance with existing anti-tuberculosis drugs make
thioridazine a compound that warrants further investigation.
Tolerability of thioridazine in humans is generally good, although
cardiotoxicity requires monitoring. With its well-established
tolerability and its activity now proven both in vitro and in vivo,
thioridazine should continue into the standard work-up of a novel
compound with known safety profile: a phase I dose-finding study
in TB patients should be done to assess the safety, tolerability,
early bactericidal activity and sterilizing capacity; consecutively, a
phase II study to proof the concept, followed by a larger phase III
study comparing efficacy of an optimized background therapy
with and without thioridazine in MDR-TB patients should be
done. Simultaneously, more active and less toxic thioridazine
derivates should be sought.
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